S Roze

578 total citations
43 papers, 452 citations indexed

About

S Roze is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Surgery. According to data from OpenAlex, S Roze has authored 43 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Economics and Econometrics and 7 papers in Surgery. Recurrent topics in S Roze's work include Diabetes Management and Research (20 papers), Diabetes Treatment and Management (18 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). S Roze is often cited by papers focused on Diabetes Management and Research (20 papers), Diabetes Treatment and Management (18 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). S Roze collaborates with scholars based in France, United States and Switzerland. S Roze's co-authors include Andrew Palmer, William J. Valentine, Simona de Portu, Katerina Zakrzewska, Jayne Smith‐Palmer, D Cobden, L Nicklasson, Mark Lamotte, Lieven Annemans and John C. Pickup and has published in prestigious journals such as Annals of Oncology, Diabetic Medicine and Diabetes Obesity and Metabolism.

In The Last Decade

S Roze

41 papers receiving 427 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S Roze France 13 360 139 121 78 63 43 452
Gemma Carreras Spain 11 189 0.5× 117 0.8× 86 0.7× 18 0.2× 46 0.7× 12 345
Catherine Domenger France 8 254 0.7× 253 1.8× 68 0.6× 77 1.0× 49 0.8× 12 412
Winston Crasto United Kingdom 8 201 0.6× 66 0.5× 50 0.4× 9 0.1× 24 0.4× 18 318
Barbara Tartaglino Italy 9 216 0.6× 87 0.6× 21 0.2× 14 0.2× 20 0.3× 20 321
Antonio Ramírez de Arellano Spain 12 177 0.5× 20 0.1× 34 0.3× 43 0.6× 28 0.4× 33 298
Elwaleed Elhassan United States 9 52 0.1× 39 0.3× 40 0.3× 23 0.3× 49 0.8× 22 272
A. Maione Italy 6 153 0.4× 56 0.4× 41 0.3× 6 0.1× 86 1.4× 8 246
Andreas Liebl Germany 10 426 1.2× 93 0.7× 33 0.3× 24 0.3× 13 0.2× 17 509
H. Lehnert Germany 6 81 0.2× 50 0.4× 72 0.6× 8 0.1× 40 0.6× 14 284
Sergio Jansen‐Chaparro Spain 9 179 0.5× 55 0.4× 67 0.6× 8 0.1× 49 0.8× 13 332

Countries citing papers authored by S Roze

Since Specialization
Citations

This map shows the geographic impact of S Roze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Roze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Roze more than expected).

Fields of papers citing papers by S Roze

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Roze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Roze. The network helps show where S Roze may publish in the future.

Co-authorship network of co-authors of S Roze

This figure shows the co-authorship network connecting the top 25 collaborators of S Roze. A scholar is included among the top collaborators of S Roze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Roze. S Roze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roze, S, et al.. (2024). International marketing trends and global advertisement: Analyzing the language barriers to efficient online marketing. World Journal of Advanced Research and Reviews. 21(1). 1295–1304.
2.
3.
Roze, S, et al.. (2019). Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. ClinicoEconomics and Outcomes Research. Volume 11. 73–82. 8 indexed citations
4.
Roze, S, et al.. (2019). PCN100 HEALTH-ECONOMIC EVALUATION OF LUNG CANCER DRUGS: DO S AND DON TS IN FRANCE. Value in Health. 22. S455–S455. 1 indexed citations
5.
Nicolucci, Antonio, et al.. (2018). Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. Nutrition Metabolism and Cardiovascular Diseases. 28(7). 707–715. 12 indexed citations
6.
7.
8.
Alfonso‐Cristancho, Rafael, et al.. (2013). Health Economic Benefits of Sensor Augmented Insulin Pump Therapy in Colombia. Value in Health. 16(7). A690–A690. 2 indexed citations
9.
10.
11.
Valentine, William J., Katrina Erny-Albrecht, Joshua Ray, et al.. (2007). Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States. Advances in Therapy. 24(2). 273–290. 18 indexed citations
12.
Roze, S, et al.. (2007). Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective. International Journal of Clinical Practice. 61(11). 1805–1811. 8 indexed citations
13.
Ray, Joshua, William J. Valentine, S Roze, et al.. (2006). Insulin therapy in type 2 diabetes patients failing oral agents: cost‐effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US*. Diabetes Obesity and Metabolism. 9(1). 103–113. 23 indexed citations
14.
Valentine, William J., Andrew Palmer, L Nicklasson, D Cobden, & S Roze. (2006). Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. International Journal of Clinical Practice. 60(9). 1138–1145. 40 indexed citations
15.
Palmer, Andrew, et al.. (2006). Klinische und gesundheitsökonomische Auswirkungen einer frühen Irbesartan-Therapie bei Typ-2-Diabetes, Hypertonie und Nierenerkrankung. DMW - Deutsche Medizinische Wochenschrift. 131(31/32). 1721–1726. 6 indexed citations
16.
Roze, S, William J. Valentine, Katerina Zakrzewska, & Andrew Palmer. (2005). Health‐economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Medicine. 22(9). 1239–1245. 74 indexed citations
17.
Palmer, Andrew, Lieven Annemans, S Roze, et al.. (2004). [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].. PubMed. 24(3). 231–8. 11 indexed citations
18.
Roze, S, et al.. (2004). Coste-efectividad de irbesartan en pacientes hipertensos con nefropatía diabética tipo II: una perspectiva española. Nefrología. 24(3). 231–238. 3 indexed citations
19.
Palmer, Andrew, et al.. (2004). Gesundheitsökonomische Aspekte der Anwendung von Irbesartan bei Patienten mit Typ-2-Diabetes, Nephropathie und Hypertonie in Deutschland. DMW - Deutsche Medizinische Wochenschrift. 129(1/2). 13–18. 14 indexed citations
20.
Palmer, Andrew, et al.. (2004). An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. Journal of Human Hypertension. 18(10). 733–738. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gemma Carreras Breakdown of academic impact, for papers by Catherine Domenger Breakdown of academic impact, for papers by Winston Crasto Breakdown of academic impact, for papers by Barbara Tartaglino Breakdown of academic impact, for papers by Antonio Ramírez de Arellano Breakdown of academic impact, for papers by Elwaleed Elhassan Breakdown of academic impact, for papers by A. Maione Breakdown of academic impact, for papers by Andreas Liebl Breakdown of academic impact, for papers by H. Lehnert Breakdown of academic impact, for papers by Sergio Jansen‐Chaparro
Rankless by CCL
2026